CCChemours Co
Chemicals & Allied Products
- Revenue
- $5.8B
- 0.4% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $3.2B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear0% of revenueOver 10% of revenue
- Payouts exceed cash flowClear56% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $6.3B | $6.8B | $6.1B | $5.8B | $5.8B | 0.4% |
| Net income | $608M | $578M | −$253M | $69M | −$386M | 659% |
| Operating cash flow | $814M | $755M | $556M | −$633M | $264M | 142% |
| Capex | $277M | $307M | $370M | $360M | $213M | 41% |
| Stock-based comp | $34M | $27M | $18M | $15M | $21M | 40% |
| Buybacks | $173M | $495M | $69M | — | — | |
| Dividends | $164M | $154M | $149M | $148M | $78M | 47% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.